A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 3,601–3,700 of 3,966
An Explainable Cryobiopsy AI Model, CRAI, to Predict Progression in Interstitial PneumoniaPreprint
Uegami, W., Okoshi, E. N., Lami, K., et al. (2025) · medRxiv · doi:10.1101/2025.08.06.25333181
Ein neues Kapitel in der Therapie der Lungenfibrose
Krauss, E. (2025) · Pneumo News · doi:10.1007/s15033-025-4201-4
Pulmonary Disease in the Older Adult
Guidot, D. M., Tighe, R. M., & Schmader, K. E. (2025) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.07.011
Butts, B., Herring, C., Park, C., Swatson, E., Watson, J., & Wharton, W. (2025) · Current Geriatrics Reports · doi:10.1007/s13670-025-00435-0
When to test for myositis antibodies in usual interstitial pneumonia on chest CT?
Guillois, E., Bertin, D., Milesi, J., et al. (2025) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2025.101211
Fibrose pulmonaire idiopathique
Philippot, Q., Guyard, A., Debray, M., & Crestani, B. (2025) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(25)87782-2
Hedgehog signalling: on the way to curing idiopathic pulmonary fibrosis
Spagnolo, P., & Khor, Y. H. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00284-x
Uzair, A., Sohail, H., Sajawal, M., Bhatti, N. I., Waseem, M., Saleem, A., Ishaq, A., Toor, Z., Ahmad, O., & Giri, B. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004001 · Cited by 1
Micallef, C. M., Belhassen, M., Fourrier, J.-M., Nolin, M., Bornier, N., Jouneau, S., Kreuter, M., Samara, K. D., & Cottin, V. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2025-003153
Interstitial pneumonia microenvironment promotes metastasis to the mediastinal lymph nodes and lungs
Maeda, R., Inomata, M., & Yamada, R. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1657948 · Cited by 1
Campisi, M., Cannella, L., Liviero, F., Tamiazzo, F., Balestro, E., Spagnolo, P., & Pavanello, S. (2026) · npj Aging · doi:10.1038/s41514-026-00434-1
Gu, J.-M., Wang, S., Zhang, S., Xiao, S.-Y., Chenchen, & Han, G.-L. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157501
Wuyts, W. A., Bonella, F., Ishii, H., Lee, J. S., Renzoni, E. A., Hadl, S., Krzykalla, J., Stowasser, S., Engel, M., & Molina‐Molina, M. (2025) · ERJ Open Research · doi:10.1183/23120541.00973-2025 · Cited by 1
Pirfenidone treatment improves ischemic muscle function in mice with chronic kidney disease
Balestrieri, N. P., Dong, G., & RYAN, T. E. (2025) · Skeletal Muscle · doi:10.1186/s13395-025-00402-5
Levra, S., Rivero, C., Giannoccaro, F., Guida, G., Bertolini, F., Carriero, V. M. A., Arrigo, E., Balbi, M., Albera, C., & Ricciardolo, F. L. M. (2025) · Biomedicines · doi:10.3390/biomedicines13112809
“The safety and efficacy of pirfenidone in the treatment of mild-to-moderate IPF is well known and several studies have been published to support it [2,3,14,15].”
Love, A. (2025) · Springer eBooks · doi:10.1007/978-3-032-12399-2_3
Song, Y., Hudson, K. J., Ye, Z., Hawley, L., Pandey, B., Zarzoso, J., Rogowski, J., Sun, Y., Rees, W. A., & Xin, Y. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1621
“17,41 Overall, the safety profile of fipaxalparant when administered alone and co-administered with pirfenidone or nintedanib support its use in future clinical trials.”
Tsuda, H., Tanino, R., Okimoto, T., Ueno, S., Tanimoto, T., Tsubata, Y., Ishikawa, N., & Isobe, T. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108520 · Cited by 2
Targeted Therapy for Interstitial Lung Disease and the Role of Nerandomilast
Moir, H., & Jinks, J. (2025) · EMJ Respiratory · doi:10.33590/emjrespir/nuyd2874
Hou, P., Wang, S., Qiu, X., Xie, W., Yin, W., Wang, C., Su, D., Zhu, Y., Xu, R., & Li, J. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c05127
Մինասյան, Ա. Մ., Meloyan, S. V., & Շ.Մ., Հ. (2025) · MEDICINE SCIENCE AND EDUCATION · doi:10.56936/18291775-2025.40-37
Gore, B., & Demi̇rel, A. (2025) · Heart & Lung · doi:10.1016/j.hrtlng.2025.11.023 · Cited by 1
Goyal, N., Andrews, J. A., Oskarsson, B., Wiedau‐Pazos, M., Kasarskis, E. J., Forrest, B. D., Zhang, R., Bracci, P. M., Davis, M. W., Azhir, A., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13123060
“In 2014, the FDA based the approvals of both nintedanib and pirfenidone on their demonstrated efficacy in slowing the decline of forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF) [15–17].”
Antifibrotic therapy in familial idiopathic pulmonary fibrosis: a comparative cohort study
Morikawa, K., Suzuki, Y., Kato, S., Kono, M., Hashimoto, D., Yokomura, K., Inoue, Y., Yasui, H., Hozumi, H., Karayama, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-27730-2
Wang, L., Hou, C., Sun, W., Ge, X., Tu, Q., Guo, H., Zhou, T., Wang, Y., Yan, L., & Xiong, W. (2025) · Research Square · doi:10.21203/rs.3.rs-8111009/v1
Drei Jahre Nutzenbewertung von neuen Arzneimitteln gemäß AMNOG
Schwabe, U. (2014) · Springer eBooks · doi:10.1007/978-3-662-43487-1_3
Interstitial Lung Diseases in Small Lung Biopsies
Fraig, M. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2575-9_5
Tabaj, G. C. (2014) · Redalyc (Universidad Autónoma del Estado de México)
Podolanczuk, A. J., Kim, J. S., Cooper, C. B., Lasky, J. A., Murray, S., Oldham, J. M., Raghu, G., Flaherty, K. R., Spino, C., Noth, I., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22611226
Keow, J., Cecchini, M. J., Jayawardena, N., Zompatori, M., JOSEPH, M. G., & Mura, M. (2022) · Figshare · doi:10.6084/m9.figshare.20024709
Aronson, K. I., Ali, M., Reshetynak, E., Kaner, R. J., Martínez, F. J., Safford, M. M., & Pinheiro, L. C. (2021) · Figshare · doi:10.6084/m9.figshare.13579036
Summer, R. S., Todd, J. L., Neely, M. L., Lobo, L. J., Namen, A. M., Newby, L. K., Shafazand, S., Suliman, S. A., Heßlinger, C., Keller, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25067232
Biondini, D., Cocconcelli, E., Bernardinello, N., Lorenzoni, G., Rigobello, C., Lococo, S., Castelli, G., Baraldo, S., Cosío, M. G., Gregori, D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361402
Podolanczuk, A. J., Kim, J. S., Cooper, C. B., Lasky, J. A., Murray, S., Oldham, J. M., Raghu, G., Flaherty, K. R., Spino, C., Noth, I., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22611220
Blumhagen, R. Z., Kurche, J. S., Cool, C. D., Walts, A. D., Heinz, D. E., Fingerlin, T. E., Yang, I. V., & Schwartz, D. A. (2024) · Figshare · doi:10.6084/m9.figshare.24586281
Tahara, M., Fujino, Y., Yamasaki, K., Oda, K., Kido, T., Sakamoto, N., Kawanami, T., Kataoka, K., Egashira, R., Hashisako, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14211837
Alqalyoobi, S., Pérez, E. R. F., & Oldham, J. M. (2020) · Figshare · doi:10.6084/m9.figshare.13204613
Alqalyoobi, S., Pérez, E. R. F., & Oldham, J. M. (2020) · Figshare · doi:10.6084/m9.figshare.13204616
Moor, C. C., Mostard, R. L. M., Grutters, J. C., Bresser, P., Aerts, J. G. J. V., Dirksen, C. D., Kimman, M. L., & Wijsenbeek, M. S. (2020) · Figshare · doi:10.6084/m9.figshare.12703761
Maqhuzu, P. N., Szentes, B. L., Kreuter, M., Bahmer, T., Kahn, N. C., Claussen, M., Holle, R., & Schwarzkopf, L. (2020) · Figshare · doi:10.6084/m9.figshare.13070887
Yamagata, A., Arita, M., Tachibana, H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457416
Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R. A., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., Olman, M. A., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11986311
Zhang, X.-L., Cao, Y., & Zheng, B. (2023) · Figshare · doi:10.6084/m9.figshare.24669857
Davis, R., Dixon, C., Millar, A. B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14544712
Keow, J., Cecchini, M. J., Jayawardena, N., Zompatori, M., JOSEPH, M. G., & Mura, M. (2022) · Figshare · doi:10.6084/m9.figshare.20024697
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646808
Wang, H.-Y., Tsai, S.-C., Lin, Y.-C., Hou, J.-U., & Chao, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.26701132
Maqhuzu, P. N., Szentes, B. L., Kreuter, M., Bahmer, T., Kahn, N. C., Claussen, M., Holle, R., & Schwarzkopf, L. (2020) · Figshare · doi:10.6084/m9.figshare.13070875
Keow, J., Cecchini, M. J., Jayawardena, N., Zompatori, M., JOSEPH, M. G., & Mura, M. (2022) · Figshare · doi:10.6084/m9.figshare.20024706
He, Z., Wang, R., Song, C., Liu, J., Chen, R., Zheng, M., Liu, W. L., Jiang, G., & Mao, W. (2024) · Figshare · doi:10.6084/m9.figshare.25449043
Wang, H.-Y., Tsai, S.-C., Lin, Y.-C., Hou, J.-U., & Chao, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.26701123
Wang, H.-Y., Tsai, S.-C., Lin, Y.-C., Hou, J.-U., & Chao, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.26701138
Wells, A. U., Jacob, J., Sverzellati, N., Cross, G., Barnett, J. L., Lauretis, A. D., Antoniou, K., Weycker, D., Atwood, M., Kirchgaessler, K.-U., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25025885
Hozumi, H., Miyashita, K., Nakatani, E., Inoue, Y., Yasui, H., Suzuki, Y., Karayama, M., Furuhashi, K., Enomoto, N., Fujisawa, T., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26420374
SELVAN, K., Reicher, J. J., Muelly, M. C., Kalra, A., & Adegunsoye, A. (2024) · Figshare · doi:10.6084/m9.figshare.26724575
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646826
Lin, T., Zhou, F., Mao, H., Xie, Z., & Jin, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26612411
Lin, T., Zhou, F., Mao, H., Xie, Z., & Jin, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26612408
Belhassen, M., Dalon, F., Nolin, M., & Ganse, E. H. V. (2021) · Figshare · doi:10.6084/m9.figshare.14538915
Ebrahimpour, A., Wang, M., Li, L., Jegga, A. G., Bonnen, M. D., Eissa, N. T., Raghu, G., Jyothula, S., Kheradmand, F., Hanania, N. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14623169
Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R. A., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., Olman, M. A., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11986305
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646817
Yang, F., Du, W., Tang, Z., Wei, Y., & Dong, J. (2023) · Figshare · doi:10.6084/m9.figshare.22617851
Rautajoki, T., Rantala, H. A., Sutinen, E., Saarto, T. H., Rajala, K., Pesonen, I., Hollmén, M., Myllärniemi, M., & Lehto, J. T. (2024) · Figshare · doi:10.6084/m9.figshare.27140893
Boateng, E., Bonilla-Martinez, R., Ahlemeyer, B., Garikapati, V., Alam, M. R., Trompak, O., Oruqaj, G., El-Merhie, N., Seimetz, M., Ruppert, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27093476
Wang, H.-Y., Tsai, S.-C., Lin, Y.-C., Hou, J.-U., & Chao, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.26701129
Jessen, H., Hoyer, N., Prior, T. S., Frederiksen, P., Karsdal, M. A., Leeming, D. J., Bendstrup, E., Sand, J. M. B., & Shaker, S. B. (2021) · Figshare · doi:10.6084/m9.figshare.14984988
He, Z., Wang, R., Song, C., Liu, J., Chen, R., Zheng, M., Liu, W. L., Jiang, G., & Mao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26695977
Rautajoki, T., Rantala, H. A., Sutinen, E., Saarto, T. H., Rajala, K., Pesonen, I., Hollmén, M., Myllärniemi, M., & Lehto, J. T. (2024) · Figshare · doi:10.6084/m9.figshare.27140896
Decaris, M. L., Schaub, J. R., Chen, C., Cha, J., Lee, G. G., Rexhepaj, M., Ho, S. S., Rao, V. R., Marlow, M. M., Kotak, P., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16835291
Podolanczuk, A. J., Kim, J. S., Cooper, C. B., Lasky, J. A., Murray, S., Oldham, J. M., Raghu, G., Flaherty, K. R., Spino, C., Noth, I., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22611223
Ikeda, K., Chiba, H., Nishikiori, H., Azuma, A., Kondoh, Y., Ogura, T., Taguchi, Y., Ebina, M., Sakaguchi, H., Miyazawa, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13311118
Yang, F., Du, W., Tang, Z., Wei, Y., & Dong, J. (2023) · Figshare · doi:10.6084/m9.figshare.22617854
Cuevas-Mora, K., Roque, W., Shaghaghi, H., Gochuico, B. R., Rosas, I. O., Summer, R. S., & Romero, F. (2021) · Figshare · doi:10.6084/m9.figshare.13787601
Rautajoki, T., Rantala, H. A., Sutinen, E., Saarto, T. H., Rajala, K., Pesonen, I., Hollmén, M., Myllärniemi, M., & Lehto, J. T. (2024) · Figshare · doi:10.6084/m9.figshare.27140899
Patel, A. S., Miller, E. R., Regis, S. M., Hunninghake, G. M., Price, L. L., Gawlik, M., McKee, A. B., Rieger-Christ, K. M., Pinto-Plata, V., Liesching, T. N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26568460
Wu, M., Wang, Z., Shi, X., Zan, D., Chen, H., Yang, S., Ding, F., Yang, L., Tan, P., Ma, R. Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24144033
Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R. A., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., Olman, M. A., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11986281
Wang, P., & Xu, Z. (2021) · Figshare · doi:10.6084/m9.figshare.16570235
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646829
Additional file 1 of Identification of targetable kinases in idiopathic pulmonary fibrosis
Higo, H., Ohashi, K., Tomida, S., Okawa, S., Yamamoto, H., Sugimoto, S., Senoo, S., Makimoto, G., Ninomiya, K., Nakasuka, T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19135951
He, Z., Wang, R., Song, C., Liu, J., Chen, R., Zheng, M., Liu, W. L., Jiang, G., & Mao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26695974
Wang, H.-Y., Tsai, S.-C., Lin, Y.-C., Hou, J.-U., & Chao, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.25530427
Štefániková, M., Doubková, M., Ovesná, P., Šterclová, M., Lacina, L., Žůrková, M., Plačková, M., Bartoš, V., Janíčková, I., Bittenglová, R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22757377
Lee, C. T., Hao, W., Burg, C., Best, J. H., Kolenic, G. E., & Strek, M. E. (2024) · Figshare · doi:10.6084/m9.figshare.26737635
Choi, M. G., Choi, S. M., Lee, J. H., Kim, J.-Y., & Song, J. W. (2023) · Figshare · doi:10.6084/m9.figshare.22613008
Zhang, H., Yang, Y., Cao, Y., & Guan, J. (2024) · Figshare · doi:10.6084/m9.figshare.26036458
Yamagata, A., Arita, M., Tachibana, H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457410
Wang, H.-Y., Tsai, S.-C., Lin, Y.-C., Hou, J.-U., & Chao, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.25530285
Singer, D., Chastek, B., Sargent, A., Johnson, J. C., Shetty, S. S., Conoscenti, C., & Bernstein, E. J. (2024) · Figshare · doi:10.6084/m9.figshare.26616373
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646805
Wang, H.-Y., Tsai, S.-C., Lin, Y.-C., Hou, J.-U., & Chao, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.26701135
Maqhuzu, P. N., Szentes, B. L., Kreuter, M., Bahmer, T., Kahn, N. C., Claussen, M., Holle, R., & Schwarzkopf, L. (2020) · Figshare · doi:10.6084/m9.figshare.13070878
Suzuki, Y., Mori, K., Aono, Y., Kono, M., Hasegawa, H., Yokomura, K., Naoi, H., Hozumi, H., Karayama, M., Furuhashi, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14955995
He, Z., Wang, R., Song, C., Liu, J., Chen, R., Zheng, M., Liu, W. L., Jiang, G., & Mao, W. (2024) · Figshare · doi:10.6084/m9.figshare.25449182
Boesch, M., Baty, F., Brutsche, M. H., Tamm, M., Roux, J., Knudsen, L., Gazdhar, A., Geiser, T., Khan, P., & Hostettler, K. (2020) · Figshare · doi:10.6084/m9.figshare.12592634
Camp, R., Smith, M. L., Larsen, B. T., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14714999
Marijic, P., Schwarzkopf, L., Schwettmann, L., Ruhnke, T., Trudzinski, F., & Kreuter, M. (2021) · Figshare · doi:10.6084/m9.figshare.16835203
Yang, F., Du, W., Tang, Z., Wei, Y., & Dong, J. (2023) · Figshare · doi:10.6084/m9.figshare.22617845
Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R. A., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., Olman, M. A., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11986290
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.